GPN Vaccines Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 36

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $13.5M

  • Investors
  • 7

GPN Vaccines General Information

Description

Developer of serotype-independent bacterial vaccines designed to provide broad protection against pathogens. The company offers a pneumococcal vaccine, a bacterial vaccine, a veterinary vaccine, a clinical-stage candidate, a whole-cell vaccine, and a serotype-independent vaccine, enabling healthcare providers to achieve immunity against all bacterial strains with a single vaccine.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • C/o Meister Seelig & Fein, PLLC
  • 125 Park Avenue, 7th Floor
  • New York, NY 10017
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • C/o Meister Seelig & Fein, PLLC
  • 125 Park Avenue, 7th Floor
  • New York, NY 10017
  • United States

GPN Vaccines Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GPN Vaccines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 03-Nov-2026 $13.5M Completed Clinical Trials - General
8. Later Stage VC (Series B2) Cancelled Clinical Trials - General
7. Later Stage VC (Series B1) 06-Jun-2024 Completed Clinical Trials - General
6. Accelerator/Incubator 07-May-2024 Completed Clinical Trials - General
5. Later Stage VC (Series A3) 31-Jan-2023 Completed Clinical Trials - General
4. Early Stage VC (Series A2) 30-Jun-2020 Completed Clinical Trials - General
3. Grant 11-Apr-2020 Completed Clinical Trials - General
2. Seed Round 28-Feb-2018 $333K $333K Completed Pre-Clinical Trials
1. Grant 01-Jan-2018 $300K Completed Pre-Clinical Trials
To view GPN Vaccines’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

GPN Vaccines Patents

GPN Vaccines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023901596-A0 Immunogenic composition Pending 22-May-2023
EP-4731253-A1 Modified streptococcal immunogen and uses thereof Pending 22-May-2023
US-20260335422-A1 Modified streptococcal immunogen and uses thereof Pending 22-May-2023
WO-2024239063-A1 Modified streptococcal immunogen and uses thereof Inactive 22-May-2023
JP-2022179236-A Streptococcal vaccine formulations and uses thereof Pending 22-May-2020 A61K39/092
To view GPN Vaccines’s complete patent history, request access »

GPN Vaccines Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GPN Vaccines Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kern Capital Venture Capital Minority
Angel (individual) Minority
Brandon Biocatalyst Venture Capital Minority
Southern Angels Angel Group Minority
Forepont Capital Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

GPN Vaccines Acquisitions (1)

GPN Vaccines’s most recent deal was a Merger/Acquisition with BacVax. The deal was made on 27-Oct-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
BacVax 27-Oct-2025 Merger/Acquisition Drug Discovery
To view GPN Vaccines’s complete acquisitions history, request access »

GPN Vaccines Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
BacVax Phoenix, AZ 2021

GPN Vaccines FAQs

  • When was GPN Vaccines founded?

    GPN Vaccines was founded in 2017.

  • Where is GPN Vaccines headquartered?

    GPN Vaccines is headquartered in New York, NY.

  • What is the size of GPN Vaccines?

    GPN Vaccines has 36 total employees.

  • What industry is GPN Vaccines in?

    GPN Vaccines’s primary industry is Drug Discovery.

  • Is GPN Vaccines a private or public company?

    GPN Vaccines is a Private company.

  • What is GPN Vaccines’s current revenue?

    The current revenue for GPN Vaccines is .

  • How much funding has GPN Vaccines raised over time?

    GPN Vaccines has raised $37.7M.

  • Who are GPN Vaccines’s investors?

    Kern Capital, , Brandon Biocatalyst, Southern Angels, and Forepont Capital Partners are 5 of 7 investors who have invested in GPN Vaccines.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process